Q-omics provides the consensus-scored FAHD2A profile across patient tissues and cancer cell-line models. FAHD2A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAHD2A is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, FAHD2A protein abundance shows 24,457 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, THCA, and PDAC as cancer lineages where FAHD2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAHD2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAHD2A survival associations across molecular data types. FAHD2A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAHD2A RNA expression–survival associations across cancer types. High FAHD2A expression shows unfavorable associations in KIRC, ACC and SKCM, but favorable associations in SCLC, MESO and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAHD2A RNA expression.
This table summarizes FAHD2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 10. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FAHD2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAHD2A shows lower tumor expression in THCA, KIRC, LIHC and BRCA and higher tumor expression in READ and LUSC. The THCA box plot shows higher FAHD2A RNA expression in normal versus tumor tissue (log2 FC = −1.757, t-test p < 0.001).
This table shows molecular features associated with FAHD2A in patient tissues and cancer cell lines. In patient samples, FAHD2A shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAHD2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SKIN.
